British journal of clinical pharmacology
A quantitative model-based approach for adavosertib dose selection in patients with uterine serous carcinoma.
Shankar Lanke, Kowser Miah, Damilola Olabode, Jincheng Yang, Srinivas Bachina, Dana Ghiorghiu, George Kirk, Didier Meulendijks, Lynda Grinsted, Victoria de Giorgio-Miller, Diansong Zhou, Megan Gibbs, Karthick Vishwanathan
Published: 202510.1002/bcp.70336
Abstract
AIMS: Adavosertib, a WEE1 inhibitor, has been studied for safety and efficacy as monotherapy and in combination therapy. The phase 2b ADAGIO trial (NCT04590248) evaluated adavosertib monotherapy for uterine serous carcinoma with a recommended dose of…
Preview only. Read the full abstract at the source